معرفی
Xiaojia (Sasha) Guo is a Research Scientist in Nephrology at Yale School of Medicine, affiliated with the Department of Internal Medicine. She holds a PhD from Rutgers University and advanced degrees from Jiangxi University and the University of Western Ontario. Her research focuses on renalase biology, vascular remodeling, and kidney injury mechanisms, with emphasis on acute kidney injury (AKI), cisplatin toxicity, and pandemic-related pathophysiology.
Key research interests include:
- Mechanisms of renalase in kidney protection and disease
- Role of APOBEC-1 in AKI recovery
- Renalase-based therapies for pancreatitis and CKD
- Clinical biomarker development for post-ERCP complications and COVID-19 outcomes
Recent publications highlight:
- Renalase as a mortality predictor in hospitalized COVID-19 patients
- Macrophage therapy for cisplatin-induced AKI
- Pancreatitis mitigation via renalase peptides
- Genetic studies of APOBEC-1 in kidney toxicity
Notable awards include multiple NIH postdoctoral fellowships and the OHSE Award (2011-2014). Her work has been supported by grants exploring innate immune responses in CKD and renalase's role in tumor angiogenesis.
Collaborations with faculty like Dr. Gary Désir and Dr. Robert Safirstein drive interdisciplinary projects in nephrology and regenerative medicine. Current research includes renalase-based nanoparticle therapies and mitochondrial dysfunction in kidney repair.
